首页> 外文期刊>International Journal of Pharmaceutics >Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability.
【24h】

Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability.

机译:地昔布洛芬的干lix剂制剂可控释并提高口服生物利用度。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The objective of this study was to achieve an optimal formulation of dexibuprofen dry elixir (DDE) for the improvement of dissolution rate and bioavailability. To control the release rate of dexibuprofen, Eudragit((R)) RS was employed on the surface of DDE resulting in coated dexibuprofen dry elixir (CDDE). Physicochemical properties of DDE and CDDE such as particle size, SEM, DSC, and contents of dexibuprofen and ethanol were characterized. Pharmacokinetic parameters of dexibuprofen were evaluated in the rats after oral administration. The DDE and CDDE were spherical particles of 12 and 19 mum, respectively. The dexibuprofen and ethanol contents in the DDE were dependent on the amount of dextrin and maintained for 90 days. The dissolution rate and bioavailability of dexibuprofen loaded in dry elixir were increased compared with those of dexibuprofen powder. Moreover, coating DDE with Eudragit((R)) RS retarded the dissolution rate of dexibuprofen from DDE without reducing the bioavailability. Our results suggest that CDDE may be potential oral dosage forms to control the release and to improve the bioavailability of poorly water-soluble dexibuprofen.
机译:这项研究的目的是获得右旋布洛芬干e剂(DDE)的最佳配方,以提高溶出度和生物利用度。为了控制地昔布洛芬的释放速率,在DDE的表面上使用EudragitRS,得到包衣的地昔布洛芬干e剂(CDDE)。表征了DDE和CDDE的理化性质,例如粒径,SEM,DSC以及右布洛芬和乙醇的含量。口服给药后在大鼠中评估了地昔布洛芬的药代动力学参数。 DDE和CDDE分别是12和19微米的球形颗粒。 DDE中的地昔布洛芬和乙醇含量取决于糊精的量,并维持90天。与地昔布洛芬粉相比,干dry剂中地昔布洛芬的溶出度和生物利用度增加。此外,用EudragitRS涂覆DDE可延迟地昔布洛芬从DDE的溶解速率,而不会降低生物利用度。我们的结果表明,CDDE可能是潜在的口服剂型,可控制水溶性差的地昔布洛芬的释放并提高其生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号